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1. Introduction
Immunosuppressive drugs are used to reduce the immune response in organ transplantation
and autoimmune disease. In transplantation, the major classes of immunosuppressive drugs
used today are: (1) glucocorticoids, (2) calcineurin inhibitors, (3) antiproliferative/antimeta‐
bolic agents, and (4) biologics (antibodies). These drugs have met with a high degree of clinical
success in treating conditions such as acute immune rejection of organ transplants and severe
autoimmune diseases. However, such therapies require lifelong use and nonspecifically
suppress the entire immune system, exposing patients to considerably higher risks of adverse
effects [1].
The pharmacokinetics of the immunosuppressive drugs is complex and unpredictable. A
narrow therapeutic index unique to each patient, as well as variable absorption, distribution,
and elimination, are characteristics of these drugs. Therapeutic drug monitoring plays a key
role in helping clinicians maintain blood and plasma levels of immunosuppressive drugs
within their respective therapeutic ranges. Variation in concentrations outside the narrow
therapeutic ranges can result in adverse clinical outcomes. Therapeutic drug monitoring
ensures that concentrations are not too high or too low, thereby reducing the risks of toxicity
or rejection, respectively. This chapter briefly reviews some immunosuppressive drugs:
cyclosporine, tacrolimus, mycophenolic acid, sirolimus, everolimus, azathioprine, daclizumab
and basiliximab, alemtuzumab and glucocorticoids. A general discussion of mechanism of
action and side effects of these immunosuppressive agents used more commonly today are
described below, followed by an overview of general principles of therapeutic drug monitoring
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and concluding with brief information about monitoring of individual immunosuppressive
agents as well as a brief description of future trends in immunosuppression therapy.
2. Mechanism of action and side effects
2.1. Cyclosporine A (CsA)
CsA is a cyclic polypeptide immunosuppressant consisting of 11 amino acids. It is produced
as a metabolite of the fungus species Tolypocladium inflatum Gams. CsA generally is recognized
as the agent that ushered in the modern era of organ transplantation, increasing the rates of
early engraftment, extending kidney graft survival, and making cardiac and liver transplan‐
tation possible. Clinical indications for CsA are kidney, liver, heart, and other organ trans‐
plantation; rheumatoid arthritis; and psoriasis. The dose of CsA varies, depending on the organ
transplanted and the other drugs used in the specific treatment protocols. Dosage is guided
by signs of rejection (too low a dose), renal or other toxicity (too high a dose), and close
monitoring of blood levels [1].
2.1.1. Mechanism of action
CsA suppresses some humoral immunity, but is more effective against T-cell-dependent
immune mechanisms such as those underlying transplant rejection and some forms of
autoimmunity. Its actions appear to be dependent upon binding to intracellular sites of action.
Because of its high lipophilicity, CsA enters cells easily to gain access to the site of action [1].
The intracellular protein most closely linked to the immunosuppressive activity of CsA is
cyclophilin. CsA forms a complex with cyclophilin, a cytoplasmic receptor protein present in
target cells. This complex binds to calcineurin to block its phosphatase activity (Table 1).
Calcineurin-catalyzed dephosphorylation is required for movement of a component of the
nuclear factor of activated T lymphocytes (NFAT) into the nucleus. Calcineurin phosphatase
activity is inhibited after physical interaction with the cyclosporine/cyclophilin complex. This
prevents Ca2+-stimulated dephosphorylation of the cytosolic component of NFAT such that
NFAT does not enter the nucleus, gene transcription is not activated, and the T lymphocyte
fails to respond to specific antigenic stimulation. By binding to cyclophilin, the antigenic
response of helper T lymphocytes is inhibited; the production of interleukin-2 and interferon-
gamma is suppressed [2-3]. In addition, production of the receptor site for interleukin-2 on T
lymphocytes is inhibited by CsA and also increases expression of transforming growth factor-
β (TGF-β), a potent inhibitor of IL-2–stimulated Tcell proliferation and generation of cytotoxic
T lymphocytes (CTL) [4-8].
2.1.2. Side effects
The principal side effects to CsA therapy are hypertension, nephrotoxicity, tremor, hirsutism,
hyperlipidemia, nausea and vomiting, gingival hyperplasia, and hepatotoxicity [1,9]. Hyper‐
tension is a common adverse effect of CsA, with the incidence decreasing over time. Generally,
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mild to moderate hypertension may occur in approximately 50% of renal transplant patients
and most cardiac transplant patients. In liver transplant patients (n=75), 27% experienced
hypertension. Incidence: 13% to 53% [9]. Discontinuation of CsA therapy may be required for
persistent blood pressure elevation despite adjustments in therapy. Antihypertensive agents
such as calcium-channel blockers may be used, with isradipine and nifedipine most appro‐
priate since they do not interfere with CsA metabolism. Other calcium-channel blockers (eg,
diltiazem and verapamil) may increase cyclosporine levels. Patients with preexisting hyper‐
tension controlled by beta-blockers may continue to receive the same therapy. Angiotensin
converting enzyme inhibitors and diuretics are not recommended [10]. Probable mechanisms
for cyclosporine induced hypertension involve increased prostaglandin synthesis, decreased
free water excretion, and decreased sodium and potassium excretion [11]. CsA is nephrotoxic,
the mechanism by which CsA causes nephrotoxicity is attributed to changes in vasomotor tone
induced by activation of the sympathetic nervous system [12]. Tremor was reported to appear
within a few days of initiating CsA therapy and was considered dose dependent. Incidence:
12% to 55% [9].
Immunosuppressive agent Site of Action
Cyclosporine and tacrolimus Calcineurin (inhibits phosphataseactivity)
Mycophenolic acid Inosine monophosphate dehydrogenase(inhibits activity)
Sirolimus and everolimus Protein kinase involved in cellcycleprogression (mTOR) (inhibits activity)
Azathioprine Deoxyribonucleic acid (falsenucleotide incorporation)
Daclizumab and basiliximab IL-2 receptor (block IL-2–mediatedT-cell activation)
Alemtuzumab Cell surface glycoprotein CD52
Glucocorticoids Glucocorticoid response elementsin DNA (regulate gene transcription)
Table 1. Sites of action of immunosuppressive agents on T-cell activation [1]
Administration of CsA adversely affects plasma lipoprotein and cholesterol levels causing
hyperlipidemia [9]. In a study CsA increased total cholesterol by 21%, low-density lipoproteins
by 31%, and apolipoproteins by 12% over 27 days [13]. Gingival hyperplasia was reported in
4% to 16% of patients treated with CsA [9]. Histologically, CsA-induced gingival overgrowth
is characterized by cellular hyperplasia along with myxomatous changes and accumulation of
collagen [14]. Reduction of the dose of CsA may result in complete resolution of gingival
hyperplasia [15,16].
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2.2. Tacrolimus (TRL)
TRL (Prograf®) is a macrolide antibiotic produced by Streptomyces tsukubaensis. It is practically
insoluble in water. TRL is indicated for the prophylaxis of solid-organ allograft rejection in a
manner similar to CsA. The recommended starting dose for TRL injection is 0.03 to 0.05
mg/kg per day as a continuous infusion. Recommended initial oral doses are 0.15 to 0.2
mg/kg per day for adult kidney transplant patients, in two divided doses 12 hours apart. These
dosages are intended to achieve typical blood trough levels in the 5 to 15 ng/mL range. Pediatric
patients generally require higher doses than do adults [1,17].
2.2.1. Mechanism of action
The compound is chemically distinct from CsA but both agents elicit similar immunosup‐
pressant effects. TRL suppresses both humoral (antibody) and cell-mediated immune re‐
sponses. Like CsA, TRL inhibits Tcell activation by inhibiting calcineurin [17]. The proposed
mechanism for this effect is binding to an intracellular protein FK506-binding protein–12
(FKBP-12), immunophilin structurally related to cyclophilin. A complex of tacrolimus-
FKBP-12, Ca2+, calmodulin, and calcineurin then forms, which inhibits the phosphatase
activity of calcineurin (Table 1). As described for CsA the inhibition of phosphatase activity
prevents dephosphorylation and nuclear translocation of NFAT and inhibits T-cell activation.
Thus, although the intracellular receptors differ, CsA and TRL target the same pathway for
immunosuppression [1,18]. The immunosuppressive activity of TRL is, however, more
marked than that of CsA. Studies on cultured CD4+ (T-helper) lymphocytes have demonstrat‐
ed that TRL is at least 100 times more potent than CsA (weight basis) in selectively inhibiting
secretion of various cytokines (i.e., interleukin-2, interleukin-3, interferon-gamma) [19,20]. The
action of TRL on lymphocytes is more difficult to reverse than that of CsA; this may be
attributable to the effect of TRL on impairing the expression of interleukin-2 receptors on
alloantigen-stimulated T-cells [19]. TRL possesses another important effect in addition to the
inhibition of IL-2 gene transcription, to be exact the ability to act as a general inhibitor of the
protein secretory pathway, which strongly suggests that the diabetogenic effect of the TRL
could be caused by the blockade of insulin secretion. This novel effect also provides an
explanation for other side-effects observed in immunosuppressive treatment [1,21,22].
2.2.2. Side effects
TRL is an established immunosuppressant for the prevention and treatment of allograft
rejection in organ transplantation. However, TRL therapy also has several adverse effects like
nephrotoxicity, hypertension, hyperkalemia, hyperglycemia, hyperlipidemia, neurotoxicity
(tremor, headache, dizziness, seizure), gastrointestinal complaints, and diabetes are all
associated with TRL use [18].
Nephrotoxicity has been reported with TRL therapy, particularly when used in high doses.
Incidence: 36% to 59% [23]. Acute nephrotoxicity is characterized by an increased serum
creatinine and/or a decrease in urine output, and is generally reversible. Chronic nephrotox‐
icity is associated with increased serum creatinine, decreased kidney graft life, and character‐
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istic histologic changes observed on renal biopsy; these changes are usually progressive. Renal
function should be monitored closely [23,24]. In systemic formulations hypertension occurred
in 13% to 89% of patients receiving TRL in clinical trials. Antihypertensive therapy may be
required. Potassium sparing diuretics, ACE inhibitors, and angiotensin receptor blockers
should be used with careful consideration since due to the potential to cause hyperkalemia.
Calcium channel blockers may be effective in treating TRL associated hypertension, but
caution is warranted since interference with TRL metabolism may require a dosage reduction.
[23,25]. Hyperlipidemia was reported as one of the more common adverse events in TRL-
treated heart transplant recipients. Incidence: 10% to 34% [23]. In clinical trials tremor has
occurred in 15% to 56% of patients receiving TRL [23,26]. In systemic formulations headache
occurred in 24% to 64% of patients receiving TRL in clinical trials. Headache may respond to
a dosage reduction [23]. In clinical trials hyperglycemia occurred in 21% to 70% of patients
receiving TRL [23]. New onset diabetes mellitus has been reported in kidney, liver, and heart
transplant patients receiving TRL therapy. Incidence: 11% to 22%. Close monitoring of blood
glucose concentrations is recommended [23,27].
2.3. Mycophenolic acid (MPA)
MPA is a secondary metabolite produced by Penicillium brevicompactum, which has antibiotic
and immunosuppressive properties used to prevent rejection of solid organ transplants [28].
It is highly soluble in aqueous media at physiological pH. The drug is marketed as the ester
prodrug mycophenolate mofetil (CellCept®) (MMF) for kidney, liver, and heart transplants
or enteric-coated mycophenolate sodium (Myfortic®) for kidney transplants [1,29].
2.3.1. Mechanism of action
MPA produces potent selective, noncompetitive, and reversible inhibition of inosine mono‐
phosphate dehydrogenase (IMPDH), an important enzyme in the de novo pathway of guanine
nucleotide synthesis (Table 1). B and T lymphocytes are highly dependent on this pathway for
cell proliferation, while other cell types can use salvage pathways; MPA therefore selectively
inhibits lymphocyte proliferation and functions, including antibody formation, cellular
adhesion, and migration [1,30]. In vitro and in vivo studies have demonstrated the ability of
MPA to block proliferative responses of T and B lymphocytes, and inhibit antibody formation
and the generation of cytotoxic T-cells [31]. In a preclinical study in mice, MPA increased
survival of heart and pancreatic islet cell allografts. Studies in rats have also demonstrated
prolonged heart allograft survival, as well as reversal of acute rejection and prevention of
rejection in the sensitized animal. Antirejection effects have been attributed to decreased
recruitment of activated lymphocytes to the graft site [32].
2.3.2. Side effects
The principal adverse effects of MPA are gastrointestinal, these include diarrhea, nausea and
vomiting; hypertension; hematologic effects (anemia and leukopenia) and neurologic effects
(anxiety asthenia dizziness headache insomnia tremor). There also is an increased incidence
of some infections, especially sepsis associated with cytomegalovirus [1,33-35]. Diarrhea was
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reported in 36.1% of renal transplant patients, 45.3% of cardiac transplant patients, and 51.3%
of hepatic transplant patients in a clinical study. Vomiting was reported in 33.9% of cardiac
transplant patients, and 32.9% of hepatic transplant patients. Nausea was reported in 23.6%
of renal transplant patients, 54% of cardiac transplant patients, and 54.5% of hepatic transplant.
The incidence of adverse gastrointestinal complications requiring dose reduction. Usually
occurs early in therapy and respond to dose reduction or switching from two to three divided
daily doses [34].
Hypertension was reported in 28.2% of renal transplant patients, 77.5% of cardiac transplant
patients, and 62.1% of hepatic transplant patients [34]. Leukopenia was 23.2% and 34.5% in
renal transplant, 30.4% in cardiac transplant, and 45.8% in hepatic transplant in a clinical study.
Complete blood counts should be performed weekly during the first month, twice monthly
for the second and third months of treatment, then monthly through the first year [34].
2.4. Sirolimus (SRL) and Everolimus (EVL)
SRL(also known as Rapamycin and Rapamune®) is a macrocyclic lactone produced by the
actinomycete Streptomyces hygroscopicus, with immunosuppressive, antitumor, and antifungal
properties. SRL appears to be synergistic with CsA in kidney transplantation, but with a
different side-effect profile. It is an immunosuppressive agent of potential benefit in clinical
liver transplantation. EVL is an analogue of SRL with immunosuppressive and antiprolifera‐
tive activity. It is closely related chemically and clinically to SRL but has distinct pharmaco‐
kinetics. The main difference is a shorter half-life and thus a shorter time to achieve steady
state concentrations of the drug [1,36].
2.4.1. Mechanism of action of SRL
SRL has been demonstrated to block the response of T- and B-cell activation by cytokines,
which prevents cell-cycle progression and proliferation. Intracellularly, sirolimus forms a
complex with cytosolic FK-binding proteins, primarily FKBP-12, considered essential for
functionality; however, the sirolimus–FKBP-12 complex does not affect calcineurin activity. It
binds to and inhibits a protein kinase, designated mammalian target of rapamycin (mTOR)
(Table 1), which is a key enzyme in cell-cycle progression. Inhibition of mTOR blocks cell-cycle
progression at the G1 to S phase transition [37,38]. Specific biochemical steps inhibited by SRL
include activation of p70S6 kinase, activation of the cdk2/cyclinE complex, and phosphoryla‐
tion of retinoblastoma protein [37,38]. SRL appears to be less nephrotoxic than CsA and TRL;
this may be related to its lack of effect on calcineurin [1,38]. In preclinical studies (in vitro and
in vivo), additive or synergistic immunosuppressive effects were observed when SRL was
combined with TRL, CsA, MMF, and brequinar [37].
2.4.2. Side effects of SRL
The use of SRL in renal transplant patients is associated with a dose-dependent increase in
serum cholesterol and triglycerides that may require treatment. Other studies have identified
hyperlipidemia and thrombocytopenia as significant SRL side effects [39]. In the other hand,
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while immunotherapy with SRL per se is not nephrotoxic, patients treated with CsA plus SRL
have impaired renal function compared to patients treated with CsA and either azathioprine
or placebo. Renal function therefore must be monitored closely in such patients. Other adverse
effects include anemia, leukopenia, thrombocytopenia, hypokalemia or hyperkalemia, fever,
and gastrointestinal effects. Delayed wound healing may occur with SRL use. As with other
immunosuppressive agents, there is an increased risk of neoplasms, especially lymphomas,
and infections [1,36,37].
2.4.3. Mechanism of action of EVL
Like SRL, EVL binds to the cytosolic immunophyllin FKBP12; both agents inhibit growth
factor-driven cell proliferation, including that of T-cells and vascular smooth muscle cells.
After binding to and forming a complex with the cytoplasmic protein FKBP-12, this complex
binds to and inhibits the mammalian Target Of Rapamycin (mTOR) and phosphorylates P70
S6 ribosomal protein kinase (a substrate of mTOR) (Table 1). The phosphorylation of P70 S6
ribosomal protein kinase by the EVL complex prevents protein synthesis and cell proliferation.
The EVL:FKBP-12 complex does not affect calcineurin activity [40,41]. Binding of EVL to
FKBP12 is weaker than that of SRL (about 3-fold), related to 40-O-alkylation, and this correlates
with a 2- to 3-fold lower in vitro immunosuppressive activity for EVL. However, the oral in
vivo activity of EVL has been at least equipotent to oral SRL in several animal allotransplan‐
tation/autoimmune disease models. This appears related to the chemical modification in EVL
(2-hydroxyethyl chain), providing more favorable pharmacokinetic properties (eg, absorption,
disposition) which compensate for relatively poor in vitro activity [40]. EVL and SRL antago‐
nize TRL based calcineurin inhibition via saturation of FKBP12 [1,42].
2.4.4. Side effects of EVL
Side effects seem to be the same as with SRL [1]. Endocrine abnormalities, including hyperli‐
pidemia and hypertriglyceridemia, have been reported with EVL treatment. Monitoring for
hyperlipidemia is recommended in all patients; diet, exercise, and lipid lowering therapy
should be initiated if hyperlipidemia occurs. In a clinical study with EVL, the most important
causes of discontinuation in 69 patients were severe infections (2.3%), pneumonitis (6.8 %),
acute rejection episode (4.1%), proteinuria (4.1%). Although the overall incidence discontinu‐
ation due to side effects was higher in the EVL than SRL group, there was no greater frequency
of severe side effects [43,44].
2.5. Azathioprine
Azathioprine is a purine antimetabolite. It is an imidazolyl derivative of 6-mercaptopurine.
Azathioprine was first introduced as an immunosuppressive agent in 1961, helping to make
allogeneic kidney transplantation possible. It is indicated as an adjunct for prevention of organ
transplant rejection and in severe rheumatoid arthritis. It has long been used as a steroid
sparing agent in a variety of clinical scenarios [1,45]. In the United States azathioprine was
usually combined with prednisone and CsA. Azathioprine was regarded as an adjunctive
agent to CsA and the combination was often called “triple therapy”. The term “adjunctive
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agent” is used to describe the immunosuppressive drugs that are used, or were developed for
use, in combination with a calcineurin inhibitor to enhance the potency of the immunosup‐
pressive protocol, as measured by a decreased incidence of acute rejection episodes [46].
2.5.1. Mechanism of action
Azathioprine inhibits purine metabolism. Following exposure to nucleophiles such as
glutathione, azathioprine is cleaved to 6-mercaptopurine, which in turn is converted to
additional metabolites that inhibit de novo purine synthesis. 6-thio-IMP, a fraudulent nucleo‐
tide, is converted to 6-thio-GMP and finally to 6-thio-GTP, which is incorporated into DNA.
Cell proliferation is thereby inhibited, impairing a variety of lymphocyte functions. Azathio‐
prine appears to be a more potent immunosuppressive agent than 6-mercaptopurine, which
may reflect differences in drug uptake or pharmacokinetic differences in the resulting
metabolites [1,45].
2.5.2. Side effects
The major side effect of azathioprine is bone marrow suppression, including leukopenia
(common), and thrombocytopenia (less common). Other important adverse effects include
increased susceptibility to infections (especially varicella and herpes simplex viruses) and
hepatotoxicity [1].
2.6. Anti-IL-2 receptor (Anti-CD25) antibodies
There are two anti–IL-2R preparations for use in clinical transplantation: daclizumab and
basiliximab. These are used for prophylaxis of acute organ rejection in adult patients. Basilix‐
imab is considered a chimeric antibody, because it consists of approximately 70% human and
30% murine proteins. This agent has low immunogenicity potential due to the incorporation
of human protein sequences. Daclizumab consists of 90% human and 10% murine components.
The effectiveness of daclizumab is comparable to that of basiliximab, with an adverse-effect
profile comparable to that seen with placebo [1,46].
2.6.1. Mechanism of action
Basiliximab binds with high affinity to the alpha subunit of the IL-2 receptor, also known as
CD25, where it acts as a receptor antagonist. The antagonistic effect on the IL-2 receptor
prevents T-cell activation and subsequent proliferation without causing lysis or cell destruc‐
tion. Daclizumab, like basiliximab, is a nondepleting monoclonal antibody that acts as an
antagonist at the CD25 subunit of T cells and received marketing approval in 1997 for induction
therapy in renal transplant recipients. In Phase III trials, the half-life of daclizumab was 20
days, resulting in saturation of the IL-2Rα on circulating lymphocytes for up to 120 days after
transplantation. In these trials, daclizumab was used with maintenance immunosuppression
regimens (CsA, azathioprine, and steroids; CsA and steroids). Subsequently, daclizumab was
successfully used with a maintenance triple-therapy regimen—either with CsA or TRL,
steroids, and MMF substituting for azathioprine. In the Phase III trials, the half-life of basilix‐
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imab was 7 days. In one randomized trial, basiliximab was safe and effective when used in a
maintenance regimen consisting of CsA, MMF, and prednisone [1,47].
2.6.2. Side effects
No cytokine-release syndrome has been observed with these antibodies, but anaphylactic
reactions can occur. Although lymphoproliferative disorders and opportunistic infections may
occur, as with the depleting antilymphocyte agents, the incidence ascribed to anti-CD25
treatment appears remarkably low. No significant drug interactions with anti–IL-2-receptor
antibodies have been described [46,47].
2.7. Alemtuzumab
The antibody alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody
that is directed against the cell surface glycoprotein CD52, which is expressed on the surface
of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and tissues
of the male reproductive system; thus, the drug causes extensive lympholysis by inducing
apoptosis of targeted cells. It has achieved some use in renal transplantation because it
produces prolonged T- and B-cell depletion and allows drug minimization [1,47].
2.7.1. Mechanism of action
Alemtuzumab antibody binds to CD52, it triggers an antibody-dependent lysis of these cells.
The depletion of lymphocytes is so marked that it takes several months or up to one year
postadministration for a patient’s immune system to be fully reconstituted ([1,47].
2.7.2. Side effects
Alemtuzumab’s mechanism of depletion is so profound that its adverse-effect profile occurs
frequently and with a high level of severity. Adverse effects associated with alemtuzumab use
include neutropenia (70%), thrombocytopenia (52%), anemia (47%), nausea (54%), vomiting
(41%), diarrhea (22%), headache (24%), dysesthesias (15%), dizziness (12%), and autoimmune
hemolytic anemia (<5%) [47].
2.8. Glucocorticoids
The introduction of glucocorticoids as immunosuppressive drugs in the 1960s played a key
role in making organ transplantation possible. Steroids are a cornerstone of immunosuppres‐
sive therapy in kidney transplantation despite their side effects and morbidity. More than 95%
of transplant recipients are treated with steroids as a usual component of clinical immuno‐
suppressive regimens. Prednisone, prednisolone, and other glucocorticoids are used alone and
in combination with other immunosuppressive agents for treatment of transplant rejection and
autoimmune disorders [1,48]. Transplantation specialists are now moving toward protocols
that reduce the incidence of infections and minimize adverse events. Most immunosuppressive
regimens are currently based on the combination of calcineurin inhibitors (CsA, TRL) with
antiproliferative agents (azathioprine, MMF) and steroids (prednisone) [49].
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2.8.1. Mechanism of action
Glucocorticoids lyse (in some species) and induce the redistribution of lymphocytes, causing
a rapid, transient decrease in peripheral blood lymphocyte counts. To effect longer-term
responses, steroids bind to receptors inside cells; either these receptors, glucocorticoid-induced
proteins, or interacting proteins regulate the transcription of numerous other genes. Addi‐
tionally, glucocorticoid-receptor complexes increase IκB expression, thereby curtailing
activation of NF-κB, which increases apoptosis of activated cells. Of central importance, key
proinflammatory cytokines such as IL-1 and IL-6 are down regulated. T cells are inhibited from
making IL-2 and proliferating. The activation of cytotoxic T lymphocytes is inhibited. Neu‐
trophils and monocytes display poor chemotaxis and decreased lysosomal enzyme release.
Therefore, glucocorticoids have broad anti-inflammatory effects on multiple components of
cellular immunity [1].
2.8.2. Side effects
Steroids are effective in reducing the incidence of acute rejection but are an important cause
of morbidity and probably mortality. Moreover, they have adverse effects on cardiovascular
risk factors such as hypertension, hyperglycemia, or hyperlipidemia, deleterious effects on
bone metabolism, and may contribute to an increased risk of infection [1,48].
3. General principles of Therapeutic Drug Monitoring (TDM)
A basic tenet of clinical pharmacology is that the pharmacologic activity of an exogenously
administered agent is related to the free drug concentration available at its receptor or ligand-
binding site. A mayor underlying hypothesis in clinical pharmacokinetics is that the concen‐
tration of the agent in blood, serum or some other measurable compartment is related to the
concentration of free (or non-bound) drug at its effector site [50]. Drugs are administered to
achieve a therapeutic objective. Once this objective is defined, a drug and its dosage regimen
are chosen for the patient. Drug therapy is subsequently managed together with steps required
to initiate therapy, this management is usually accomplished by monitoring incidence and
intensity of both therapeutic and toxic effects.
3.1. Therapeutic range
The therapeutic range (therapeutic index) is the ratio between the toxic dose and the thera‐
peutic dose of a drug. The closer this ratio is to 1, the more difficult the drug is to use in clinical
practice. The therapeutic index for immunosuppressant drugs is very low, whereas that for
amoxicillin is extremely high. Clinical use of drugs with a narrow therapeutic index has led to
the monitoring of drug concentrations in patients – therapeutic drug monitoring – in which
the plasma concentration of a drug is measured and the dose adjusted to achieve a desired
therapeutic drug concentration. Generally defined as the range of drug concentrations
associated with maximal efficacy and minimal toxicity, there is currently no standard defining
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an acceptable level of toxicity or efficacy, nor are there consistent procedures used to establish
a therapeutic range [51].
In general, a therapeutic range should never be considered in absolute terms, as it represents
no more than a combination of probability charts. In other words, a therapeutic range is a range
of drug concentrations within which the probability of the desired clinical response is relatively
high and the probability of unacceptable toxicity is relatively low [52].
Since the development of the range is probabilistic in nature, a concentration that is within the
“therapeutic range” for a given drug does not exclude the possibility that signs and symptoms
of toxicity experienced by an individual patient are related to the monitored drug. A concen‐
tration outside of the range also does not indicate that a patient will experience toxicity or
reduced efficacy; however, the likelihood of either is certainly lower [51]. It is important to
recognize that the therapeutic range is not necessarily valid outside of the population used to
establish it. This is particularly critical for immunosuppressive drugs, as most patients that are
treated with these drugs receive additional immunosuppressive agents. A change in dosing
of one drug may have a profound impact on the pharmacodynamic relationship of another.
The nature of the transplanted organ (e.g., cadaveric versus living-related donor kidneys), age,
and co-morbid illness can all have important influences on the pharmacodynamic response.
The importance of these factors should not be ignored [51].
3.2. Interpretation of plasma drug concentration
The process of selecting the most appropriate dosage regimen to achieve concentrations in a
relatively narrow range may be complicated by unpredictable intrapatient and interpatient
variability in the drug’s pharmacokinetics. A sophisticated application of pharmacokinetic
principles, incorporating prior and subsequent measures of drug concentration and effects,
can improve the quality of one’s predictions. Although a single “best” approach to using drug
concentrations does not exist for every drug, it is imperative to realize that without a systematic
approach to therapeutic drug concentration monitoring, drug concentrations may be uninter‐
pretable, unhelpful and potentially harmful. It thus becomes essential to recognize the key
elements of clinical pharmacokinetics and pharmacodynamics, and to develop strategies to
perform and use them most effectively [52].
There are a number of advantages to therapeutic drug monitoring that provide the clinician
with clinically useful information. Plasma drug concentrations in conjunction with a thorough
assessment of the patient’s clinical status and the therapeutic goals to be achieved provide a
means of successfully and rapidly individualizing a patient’s therapeutic regimen to assure
optimal benefits con minimal risk. Therapeutic drug measuring is only one part of therapeutic
drug monitoring that provides expert clinical interpretation of drug concentration as well as
evaluation based on pharmacokinetic principles. Expert interpretation of a drug concentration
measurement is essential to ensure full clinical benefit. Clinicians routinely monitor drug
pharmacodynamics by directly measuring the physiological indices of therapeutic responses,
such as lipid concentrations, blood glucose, blood pressure, and clotting [53].
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Anyone involved in the utilization of information derived from TDM must always bear in
mind that the interpretation of plasma drug concentration must always be carried out in
conjunction with an assessment of the clinical status of the patient. Therapeutic ranges should
more correctly be described as optimal concentrations. According to the definition mentioned
above, the therapeutic range (optimal concentration) of a drug is that concentration of drug
present in plasma or some other biologic fluid or tissue that provides the desired therapeutic
response in most patients. The severity of the disease process determines the amount of drug
necessary to achieve a given therapeutic effect. Thus, it is quite possible that a patient may
achieve the desired therapeutic effect at a plasma concentration well below the optimal range.
Conversely, some patients will not achieve the desired therapeutic effect even when plasma
concentrations are elevated into the toxic range. If the desired therapeutic effect is achieved at
suboptimal plasma concentrations, every attempt should be made to avoid the prescription of
additional drugs simply to increase the plasma concentration into what is commonly referred
to as the therapeutic range. Obviously, the interpretation of plasma drug concentration must
take into account the various factors that can alter the steady state plasma concentrations
achieved on a given dosage form [54].
3.3. Therapeutic Drug Monitoring (TDM)
Individualizing a patient’s drug therapy to obtain the optimum balance between therapeutic
efficacy and the occurrence of adverse events is the physician’s goal. However, achieving this
goal is not always straight forward, being complicated by within and between patient
variability in both pharmacokinetics and pharmacodynamics. In the early 1960’s new analyt‐
ical techniques became available allowing the measurement of the low drug concentrations
seen in biological fluids during drug treatment. This offered the opportunity to reduce the
pharmacokinetic component of variability by controlling drug therapy using concentrations
in the body rather than by dose alone. This process became known as therapeutic drug
monitoring [55].
The aim of TDM is to optimize pharmacotherapy by maximizing therapeutic efficacy, while
minimizing adverse events, in those instances where the blood concentration of the drug is a
better predictor of the desired effect(s) than the dose. The reasons why these principles have
gained wide acceptance include the following: (1) although imperfect, a better relationship
often exists between the effect of a given drug and its concentration in the blood than between
the dose of the drug and the effect; (2) a thorough understanding of pharmacokinetics, i.e., the
processes of drug absorption, distribution, metabolism, and drug excretion in individual
patients and in patient populations is available; and (3) the development of reliable and
relatively easy to use drug-monitoring assays. In addition, TDM can also be useful in cases in
which compliance is in question, where it is not clear if the right drug is being taken, where
dosage adjustment is required as a result of drug–drug or drug–food interactions, and where
intoxication is suspected.
TDM is more than simply the analysis of a single drug concentration in the blood of a patient
and a report of this number. It also comprises interpretation of the value measured using the
mathematical (pharmacokinetic) principles mentioned above, drawing the appropriate
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conclusions about the result, and advising the physician who ordered the test how to optimize
treatment. It is important to apply a uniform definition of TDM here, because different
definitions have previously been used in cost-effectiveness studies and reviews of TDM.
Consequently, comparisons have been made based on different approaches, which may
influence the results. The International Association for Therapeutic Drug Monitoring and
Clinical Toxicology has adopted the following definition:
Therapeutic drug monitoring is defined as the measurement made in the laboratory of a parameter that,
with appropriate interpretation, will directly influence prescribing procedures. Commonly the meas‐
urement is in a biologic matrix of a prescribed xenobiotic, but it may also be of an endogenous compound
prescribed as replacement therapy in an individual who is physiologically or pathologically deficient in
that compound. This definition places TDM within the total therapeutic approach and should
give not only more emphasis to the medication and patient-safety aspects of pharmacotherapy,
but also more insight into why there are differences in efficacy among different patients. This
definition implies that clinical pharmacologists have an active involvement in drug therapy,
something that is not yet realized in many countries [56].
3.3.1. Why TDM for immunosuppressants?
For a drug to be a suitable candidate for therapeutic drug monitoring it must satisfy the
following criteria [55]:
1. There should be a clear relationship between drug concentration and effect.
2. The drug should have a narrow therapeutic index; that is, the difference in the concen‐
trations exerting therapeutic benefit and dose causing adverse events should be small.
3. There should be considerable between-subject pharmacokinetic variability and, therefore,
a poor relationship between dose and drug concentration/response.
4. The pharmacological response of the drug should be difficult to assess or to distinguish
form adverse events.
The most commonly used immunosuppressants require TDM because of their narrow
therapeutic index and significant variability in blood concentrations between individuals. In
transplant recipients, both supratherapeutics and subtherapeutics drug concentrations can
have devastating results. At subtherapeutics drug concentrations, the transplant recipient is
at risk for allograft rejection. At supratherapeutics drug concentrations, the patient is at risk
for over-immunosuppression which can potentially lead to infection or drug specific side
effects. It is it known that neurological and gastrointestinal side effects occur more frequently
at higher concentrations of TRL [53]. Immunosuppressants display significant interindividual
variability in plasma drug concentrations, which creates the demand for TDM when such
drugs are used.
3.3.2. Factors contributing to the variability
Immunosuppressants display significant interindividual variability in plasma drug concen‐
trations, which creates the demand for TDM when such drugs are used. It is appropriate to
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look into the multitude of factors that contribute to the interindividual variability. Some of the
factors include drug-nutrients interactions, drug-disease interactions, renal insufficiency,
inflammation and infection, gender, age, polymorphism and liver mass. Drug nutrient
interactions are becoming very widely appreciated. The metabolism of drugs sometimes also
depends on the type of diet taken by the patients. Renal transplant patients may have reduced
oral bioavailability for TRL. When given with meals, especially with high fat content food, oral
bioavailability of TRL decreases [57].
To avoid the possible effect of food on TRL bioavailability, the drug should be given at a
constant time in relation to meals. Several studies have demonstrated that grapefruit juice can
increase plasma concentrations of CsA by inhibiting CYP3A-mediated metabolism and by
increasing drug absorption via inhibition of P-glycoprotein (P-gp) efflux transporters. Also,
oral TRL should not be taken with grapefruit juice since this vehicle inhibits CYP3A4 and/or
P-gp contained in the gastrointestinal tract and markedly increases bioavailability. Similarly,
drug disease interactions can also contribute to interindividual variability in plasma concen‐
tration of immunosuppressants. Renal insufficiency can result in an altered free fraction of
MPA due to the reduction in protein binding. MMF is rapidly converted to its active form,
MPA, upon reaching the systemic circulation. MPA is metabolized to its glucuronide metab‐
olite, MPA glucuronide (MPAG), by glucoronyl transferases in the liver and possibly else‐
where. MPAG is then excreted by the kidney. MPA is extensively and avidly bound to serum
albumin. Previous studies have demonstrated that it is only the free (non-protein-bound)
fraction of MPA that is available to exert its action. In vivo and in vitro studies demonstrate that
renal insufficiency decreases the protein binding of MPA and increases free drug concentra‐
tions. This decrease in protein binding seems to be caused both by the uremic state itself and
by competition with the retained metabolite MPAG. The disposition of MPA in patients with
severe renal impairment may be significantly affected by this change in protein binding [58].
The concomitant administration of TRL and nonsteroidal anti-inflammatory drugs has been
described as a possible cause of increased TRL nephrotoxicity because of the reduction of
vasodilator prostaglandin synthesis through a blockade of the enzyme cyclo-oxygenase.
Coadministration of ibuprofen and TRL has resulted in acute renal failure. Drugs such as
aminoglycosides, cotrimoxazole (trimethoprim/sulfamethoxazole), amphotericin B and
aciclovir, which cause significant renal dysfunction on their own, may also enhance TRL
nephrotoxicity in the absence of careful monitoring of both renal function and drug concen‐
trations [59].
It has been demonstrated that the in vitro metabolism of CsA in human liver microsomes was
significantly reduced by TRL [60]. Interaction between MMF and TRL or CsA is probably
related to a possible inhibitory effect of TRL on MPA metabolism and an inhibition of the
enterohepatic recirculation of MPA by CsA, resulting in a substantial reduction in the MMF
dosage when associated with TRL as compared with CsA. This has been reported in pediatric
renal allograft patients and animal models [61,62].
Gender  also  influences  drug  concentration.  Biologic  differences  exist  between  men  and
women that  can  result  in  differences  in  responses  to  drugs.  Both  pharmacokinetic  and
pharmacodynamic differences between the sexes exist, with more data on pharmacokinet‐
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ic  differences.  Bioavailability  after  oral  drug dosing,  for  CYP3A substrates  in  particular,
may be somewhat higher in women compared to men [63]. It is known that MPA is pri‐
marily metabolized in the liver to its MPAG derivative. Morissette et al., found that men
treated with MMF and TRL showed a lower ratio than patients treated with this couple
of  drugs,  confirming that  TRL inhibits  glucuronidation of  MPA. Because MPAG can fa‐
vor the elimination of MPA, they concluded that gender differences and cotreatment with
TRL must be taken into consideration when MMF is being administered [64]. Velickovic
et  al.,  investigated the gender differences in pharmacokinetics of  TRL, their  result  show
remarkable gender-related differences between women and men after the first  oral  dose
among kidney transplant recipients on quaternary immunosuppressive therapy, including
TRL, MMF, methylprednisolone and basiliximab [65].
Likewise, age can also contribute to interindividual difference in immunosuppressant plasma
concentration. Pharmacokinetic parameters observed in adults may not be applicable to
children, especially to the younger age groups. In general, patients younger than 5 years of
age show higher clearance rates regardless of the organ transplanted or the immunosuppres‐
sive drug used [66]. Young children (1–6 years of age) appear to need higher doses per kilogram
body weight of TRL than older children and adults to maintain similar trough concentrations.
The reason for this age-related faster clearance rate is unknown [67]. Pediatric transplant
recipients require higher doses of CsA to maintain blood concentrations equal to those found
in adults [68]. Studies using intravenous CsA demonstrate that this is not because of any
metabolic differences, as CsA clearance is not related to age [69].
Polymorphism has demonstrated functional consequences of many drug metabolizing
enzymes. For example, CsA is known substrate for CYP3A4/5 and P-gp. CYP3A5 is one of the
main CYP3A enzymes and its expression is clearly polymorphic and shows ethnic dependence.
TRL is primarily metabolized by cytochrome P450(CYP)3A enzymes in the gut wall and liver.
It is also a substrate for P-gp, which counter-transports diffused TRL out of intestinal cells and
back into the gut lumen. Age-associated alterations in CYP3A and P-gp expression and/or
activity, along with liver mass and body composition changes would be expected to affect the
pharmacokinetics of TRL in the elderly [70]. The importance of interethnic differences in the
pharmacokinetics of immunosuppressants has been recognized as having a significant impact
on the outcome of transplantation. In a retrospective analysis Fitzimmons et al., found that the
oral bioavailability of TRL in African American healthy volunteers and kidney transplant
patients was significantly lower than in non-African Americans, but there was no statistically
significant difference in clearance [71]. These results were confirmed in a healthy volunteer
study. The absolute oral bioavailability of TRL in African American and Latin American
subjects was significantly lower than in Caucasians. The results suggested that the observed
ethnic differences in TRL pharmacokinetics were, instead, related to differences in intestinal
P-glycoprotein-mediated efflux and CYP3A-mediated metabolism rather than differences in
hepatic elimination [72].
Other ethnic groups such as the Japanese populations are not different from the Caucasian
population because their transplant outcomes were comparable under usual TRL dosages [73].
All this factors contribute to the variability of immunosuppressant concentrations which has
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to be maintained within therapeutic range in order to achieve the optimal benefit of drug
therapy, rendering TDM necessary for these drugs.
4. Monitoring of individual immunosuppressive agents
4.1. Cyclosporine (CsA)
The introduction of CsA in the early 1980s was immediately associated with an enhanced one
year renal allograft survival; however, the argument for the therapeutic monitoring to optimize
efficacy and safety, has been discussed in the last 25 years and it is still debated [74].
4.1.1. Therapeutic monitoring
4.1.1.1. Trough concentration (C0) monitoring
Over the past two decades, there have been changes to recommended CsA dosing, changes in
concomitant medications, and one major change to the oral drug formulation. Lately, there
has also been the introduction of generic formulations of CsA [75]. In 1988, in a prospective
study showed that although C0 (trough concentration) levels of CsA correlated poorly with
dose, Cmax was significantly correlated with dose, Area Under the Curve (AUC) and elimi‐
nation half-life (t1/2). Those who suffered acute rejection had a significantly lower Cmax by 15–
31% [76]. The problem with this method for adjusting the dosage of CsA is that it relies on only
one aspect of CsA pharmacokinetics, the predose or trough concentration. With the original
formulation of CsA, Sandimmune®, this was the best practice, but during the conversion of
patients from that formulation to the improved formulation, Neoral® the 2 h post-dose
concentration has been advocated as a single concentration monitoring alternative to C0 [77].
The microemulsion formulation of CsA, Neoral®, makes CsA pharmacokinetics more
predictable and reduces the effects of bile and food on absorption [78]. Nevertheless the
predose concentration is still widely used in clinical practice. Currently, most transplant
centers measure a single steady-state CsA concentration as either a C0 predose trough or 2
hours postdose, while some conduct multiple measurements to determine CsA AUC estimates
[79]. The target predose concentrations varied not only with transplanted organ and time after
transplant but also with the analytical method used. The therapeutic range of CsA used by
clinicians varies greatly according to the type of assay used to measure CsA and whether blood
or serum concentrations are determined by the clinical laboratory.
Thus, it has reported by high pressure liquid chromatography, monoclonal fluorescence
polarization immunoassay (monoclonal TDx assay, Abbott Diagnostics®), or monoclonal
radioimmunoassay (various manufacturers), the level of therapeutic concentrations in blood
are 10-400 ng/mL. By high pressure liquid chromatography, monoclonal fluorescence polari‐
zation immunoassay (monoclonal TDx assay, Abbott Diagnostics®), or monoclonal radioim‐
munoassay (various manufacturers), the level of therapeutic concentrations in serum are
50-150 ng/mL. By polyclonal fluorescence polarization immunoassay (monoclonal TDx assay,
Abbott Diagnostics®), or polyclonal radioimmunoassay (various manufacturers) the level of
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therapeutic concentrations in blood are 200-800 ng/mL, and by polyclonal fluorescence
polarization immunoassay (monoclonal TDx assay, Abbott Diagnostics®), or polyclonal
radioimmunoassay (various manufacturers), the level of therapeutic concentrations in plasma
are 100-400 ng/mL [79].
4.1.1.2. Area under the blood concentration-time curve (AUC)
The first steps towards the development of a more precise monitoring strategy for CsA resulted
from the landmark studies by Lindholm and Kahan and Kahan et al., which identified a link
between the pharmacokinetics of CsA and clinical outcomes in the individual transplant
recipient [80,81]. The area under the concentration-time curve for CsA over a 12-hour drug
administration interval (AUC0-12h) was a more precise predictor of graft loss and incidence of
acute rejection than other parameters, including the C0. Since then, subsequent studies on the
pharmacokinetics of CsA in renal transplant patients have identified that intrapatient varia‐
bility in AUC values over time was directly correlated with the risk of chronic rejection [77,82].
Proper calculation of AUC requires administration of a dose, followed by blood collection
according to an intensive sampling strategy. Concentration values obtained are used to
calculate AUC, usually by the trapezoidal method [78]. Some advantages of AUC monitoring
are that it is the most precise indicator of drug exposure, can characterize abnormal absorption
patterns, appears to be a predictor of clinical outcomes, generates a concentration-time profile,
allows calculation of oral pharmacokinetic parameters, and reduces the problems associated
with laboratory errors and single concentrations [74,83,84].
Despite its appealing potential advantages, the major disadvantage of AUC monitoring is its
inherent need for multiple blood samples. The increased number of samples required, makes
AUC monitoring impractical for routine clinical use, more expensive in the short term because
of increased sample collection, analysis and interpretation of results, and inconvenient for
patients, especially those in an outpatient setting [77,85]. AUC has been advocated as a better
parameter to monitor than trough concentrations, because trough concentrations give no
indication of exposure to CsA. For example, 2 patients could have the same trough concen‐
tration, but one could have a much lower AUC and, therefore, exposure to CsA. Unfortunately,
AUC monitoring is not clinically feasible because of the added time, expense and inconven‐
ience required to collect a sufficient number of samples to properly calculate AUC. Although
the full AUC for CsA has been demonstrated as being a sensitive monitoring tool, there may
be an alternative approach to the determination of the degree and variability of CsA exposure
in the individual patient [77,83].
4.1.1.3. Two hours post dose concentration monitoring (C2)
This approach, which is termed ‘absorption profiling’, has the underlying rationale that the 4-
hour absorption phase following administration provides measurements that are more
informative than C0 monitoring in the assessment of likely CsA exposure and subsequent
clinical response [86,87]. AUC0-4h monitoring is a sensitive tool used to optimize CsA immu‐
nosuppression in renal transplant recipients. However, the tool is not practical in the clinical
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setting because of 3 drawbacks: (1) it requires multiple sampling of blood for determination
of the AUC0-4h, (2) the actual value requires a mathematical calculation step, and (3) the test
may be too expensive for many clinical hospitals or institutions because of the use of added
costly laboratory tests for CsA concentrations and the subsequent increase in workload.
Therefore, the search for a single blood-sampling point that best reflects the sensitivity of
AUC0-4h was the focus of several research initiatives that resulted in a broad approval for C2
monitoring [82,85]. This method is done by measuring either the area under the blood CsA
concentration-time curve in the first hours after dose, AUC0-4 or, more simply, by measuring
the blood CsA concentration at 2 hours after dose, C2 [82].
In the novo patients this monitoring method has led to result in the following clinical benefits
compared with trough concentration monitoring [88]: (1) reduced incidence of acute rejection,
(2) reduced severity of rejection episodes and (3) reduced incidence of nephrotoxicity.
4.1.1.4. Bayesian forecasting
The initial pharmacokinetic models for CsA were complicated by the nonlinear, segmented,
zero order absorption of the drug from the gut [77,89]. Bayesian forecasting is a TDM tool that
has been successfully used clinically in the monitoring of drugs that have a narrow therapeutic
index, including antiepileptic drugs, theophylline and aminoglycosides; however, although
Bayesian forecasting has proven useful clinically with other drugs, this is not the case with
CsA [78]. Bayesian forecasting, in its modern form, was first proposed in 1979 by Sheiner et
al. [90]. Since that time, user-friendly computer programs that perform this technique have
become widely available. These programs are capable of calculating dosage regimens and
pharmacokinetic parameters, as well as predicting drug concentrations by blending popula‐
tion values with patient-specific values [78]. However, these methods were technically
complex and were not practical or successful for individualizing CsA therapy in a routine
clinical setting and therefore did not gain widespread use. The introduction of Neoral, with
its less variable and more predictable blood concentration profile, has rekindled interest in the
pharmacokinetic modeling of CsA and in the use of Bayesian forecasting to predict CsA blood
concentrations [77].
4.2. Tacrolimus (TRL)
The  therapeutic  range  for  TRL  used  by  most  transplantation  centers  is  5–20  ng/mL  in
blood. Although, plasma TRL concentrations have been measured and an equivalent ther‐
apeutic  range in this  matrix  suggested (0.5–2 ng/mL),  the two most  widely used assays
for the drug use blood samples.  Because this drug is extensively bound to erythrocytes,
blood concentrations average about  15 times greater  than concurrently measured serum
or  plasma concentrations  [57,79,91].  As  a  result,  whole  blood has  become the  principal
sample used for TRL concentration monitoring, with extraction accomplished through cell
lysis  and protein  denaturation steps  that  are  similar  or  identical  to  those  used for  CsA
analysis [51]. The pharmacokinetics of TRL is highly variable. Since TRL shares many of
the pharmacokinetic  and pharmacodynamic problems associated with CsA the rationale
for TDM is similar. Although the feasibility of a limited sampling scheme to predict AUC
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has been demonstrated, as yet, through or predose whole blood concentration monitoring
is still the method of choice [55].
4.2.1. Therapeutic monitoring
TRL whole-blood through concentrations have been found to correlate well with the area
under the concentration-time curve measurements in liver, kidney and bone marrow trans‐
plant recipients (r= 0.91-0.99). Thus, through concentrations are good index of overall drug
exposure, and are currently used for routine monitoring as part of patient care posttransplan‐
tation [91,92]. This approach offers the opportunity to reduce the pharmacokinetic variability
by implementing drug dose adjustments based on plasma/blood concentrations. Drug levels
are obtained as predose (12 hours after previous dose) trough concentrations in whole blood
[88]. These trough levels correlate reasonably well with area under the curve, with total area
under the curve being an accurate measure of drug exposure [94].
Therapeutic ranges of TRL after kidney transplantation are reported as a range for various
times after transplant: 0-1 month, 15-20 μg/L; 1-3 months, 10-15 μg/L; and more than 3 months,
5-12 μg/L [95]. TRL blood concentrations are monitored 3 to 7 days a week for the first 2 weeks,
at least three times for the following 2 weeks, and whenever the patient comes for an outpatient
visit thereafter [96]. On the basis of the terminal half-life of TRL, it was suggested to start
monitoring blood concentrations 2 to 3 days after initiation of TRL treatment after the drug
has reached steady state. However it is important to reach effective drug concentrations early
after transplantation to decrease the risk of acute rejection and to avoid excessive early
calcineurin inhibitors concentrations that may be severely damaging after reperfusion of the
transplanted organ [97].
The frequency of TDM of TRL should be increased in the case of suspected adverse events or
rejection, when liver function is deteriorating, after dose adjustments of the immunosuppres‐
sants, change of route of administration, or change of drug formulations, when drugs that are
known to interact with CYP3A or P-gP are added or discontinued, or when their doses are
changed, in case of severe illness that may affect drug absorption or elimination such as severe
immune reactions and sepsis, or if noncompliance is suspected [98].
4.3. Mycophenolic acid (MPA)
In 1995,  for preventing rejection in renal  transplant patients,  MMF, the morpholinoethyl
ester prodrug from MPA was approved for clinical use. This drug has since become the
predominant anti-metabolite immunosuppressive used in the transplant setting. Although
the  current  labeling  information  for  MMF  does  not  indicate  any  need  for  therapeutic
monitoring of plasma MPA concentrations, there were a number of studies showing a re‐
lationship between MPA pharmacokinetics and clinical outcome [99].  Definitive determi‐
nation  of  the  pharmacokinetics  of  the  drug  in  renal  allograft  recipients  after
transplantation is not without difficulty. In principle, substantial changes in pharmacoki‐
netics  could  be  produced  by  changes  following  transplantation,  both  in  the  immediate
post-transplant period (reflecting rapid alterations in drug therapy, renal function, hemo‐
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dynamics  and  gastrointestinal  motility)  as  well  as  more  gradual  changes  (reflecting
change in bodyweight, plasma proteins and organ function) [100]. The greatest variability
in MPA pharmacokinetic is noted in the initial 2 months following transplantation, when
adequate immunosuppression is critical to graft function and survival. It has also become
apparent from longer term pharmacokinetic studies that exposure to MPA increases over
time due to reduced clearance of  the drug.  A possible  additional  factor  that  could con‐
tribute  to  the  higher  oral  clearance  of  MPA early  after  transplantation  is  corticosteroid
therapy, which is significantly higher in that period but then is tapered to low dose lev‐
els  or  completely  withdrawn.  Based  upon  the  marked  pharmacokinetic  variability  ob‐
served with MPA and the pharmacodynamic relationship of pharmacokinetic parameters
to rejection outcome, several scientific societies and consensus conferences have advocat‐
ed the use of concentration monitoring for patients undergoing treatment with MMF or
enteric-coated MPA [101].
4.3.1. Therapeutic monitoring
The incorporation of MMF into immunosuppressive regimens has been associated with
decrease rates of acute rejection and decreased chronic allograft loss. Indications for TDM of
mycophenolates were reviewed in a consensus meeting [101]. They included high-risk
patients, patients with delayed graft function, or patients with immunosuppressive protocols
excluding induction therapy or steroids or calcineurin inhibitor or patients with calcineurin
minimization. Most of these patients (especially high-risk patients) are often excluded from
the clinical trials. In fact, MPA TDM is currently only used in a few transplant centers on a
routine basis, whereas a few others only checked MPA exposure in case of unexpected acute
rejection or adverse event or drug interaction. Most of the centers never measure MPA. It is
clear that the use of MPA TDM is conditioned by the faith of the physicians in its use, local
availability of MPA measurements, and organization of the nursing staff [102].
4.3.1.1. Trough concentration (C0) monitoring
Although a relationship between AUC and outcome exists, the clinical utility of concentration
monitoring, particularly C0 monitoring for MMF, has been questioned. Over the past decade,
several studies were conducted to evaluate the clinical utility of prospective concentration
controlled MMF therapy. While these studies were anticipated to fully clarify the utility of
monitored MMF therapy, the outcomes from these studies are conflicting and have done little
to settle the controversies surrounding this area of therapeutic drug monitoring [100]. With
trough concentration, plasma concentration of MPA is measured immediately before a dose,
it is easy to measure because only -ask patient to return to give sample, it is immediately before
a dose, and only requires single simple possible association between C0 and decreased rejection
noted in transplant recipients. However this method represents some disadvantages. Timing
may not be accurate (depends on remembering time of last dose). Timing may vary from the
“ideal” (12 h after last dose) by several hours. There is no high-level evidence of a strong
association between C0 and outcome, or between C0 and AUC0–12, C0 is not a very informative
time point for estimation of individual pharmacokinetic parameters. Single time-point samples
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such as the trough concentration or others do not correlate well with the MPA AUC, especially
in the early posttransplantation period [103].
4.3.1.2. Limited sampling strategies for estimation of MPA AUC
The dose interval MPA AUC0–12 h is generally regarded as the most reliable pharmacokinetic
parameter index of risk for acute rejection but is impractical to measure in routine clinical
practice. Single time-point samples such as the trough concentration or others, do not correlate
well with the MPA AUC, especially in the early posttransplantation period renal transplant
patients and for regimens that include MMF plus CsA, TRL, or SRL [104]. Therefore, assess‐
ment of whether C0 concentrations or other single time points correlate well with the AUC is
important for establishing routine monitoring of the drug. Apart of the C0 level other single
time points after MMF dosing are examined for their ability to predict full AUC values. A full
MPA AUC typically requires at least eight blood samples during 12 hour dose interval. In
clinical practice this is impractical; therefore, abbreviated sampling schemes involving the
collection of there to five plasma samples have been investigated. The abbreviated sampling
approach has provided estimations of MPA AUC with high correlations (r2>0.8). Several
models have been developed all of them in renal transplant patients [105-108].
4.4. Sirolimus (SRL)
SRL (formerly known as rapamycin) is a macrolide antibiotic with immunosuppressive
properties that was introduced relatively recently (September 1999) into clinical practice for
maintenance therapy in organ transplantation [109]. Pharmacokinetics studies of SRL in renal
transplant patients have been shown great variability between patients. Several features
contribute to the interpatient pharmacokinetic variability observed with SRL and can include
any combination of the following: absorption, distribution, metabolism and/or excretion [110].
This drug presents a rapid gastrointestinal absorption (tmax from 0.33 to 5 hours) as well as a
low (mean value 14%) and variable bioavailability. It has been reported that SRL is a substrate
for the multidrug P-glycoprotein transporter and that the biotransformation of SRL is medi‐
ated by CYP3A enzymes. Accordingly, considerable variability in its pharmacokinetic
parameters may be expected (apparent blood clearance rates after oral administration from 87
to 416 mL/h/kg). In addition, the disposition of SRL in humans includes a large volume of
distribution, a long half-life (35 to 95 hours) and dose proportionality for Cmax and AUC. Also,
some interracial variability and an influence of hepatic dysfunction have been noted with SRL
[111]. Although structurally similar to TRL, SRL has a novel mechanism of action, which leads
to synergy with CsA. The long half-life of the drug necessitates a loading dose to achieve
therapeutic concentrations quickly, and also allows for once daily administration. Highly
variable absorption and metabolism of the drug result in large differences in blood concen‐
trations among patients receiving the same dose. Efficacy for the prevention of acute rejection
episodes, and the rate of common adverse effects (thrombocytopenia, leucopenia and hyper‐
triglyceridemia), are concentration-dependent [112].
Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents
http://dx.doi.org/10.5772/54910
329
4.4.1. Therapeutic monitoring
Clinical data suggest that the immunosuppressive efficacy and the occurrence and severity of
adverse effects of SRL correlate with blood concentrations [112]. Drug interactions with
concomitant immunosuppressant medications will alter SRL whole blood concentrations. The
appropriate SRL through concentration at steady state (Cmin,ss) for acute rejection episode
prophylaxis is a function of the concomitant immunosuppressive regimen. When it is used as
base therapy with azathioprine and prednisone, a regimen stipulating initial Cmin,ss values
equal to 30 μg/L during the first 2 months, and 15 μg/L(LC/UV assay) thereafter, led to a 41%
rate of acute rejection episodes among 41 cadaveric kidney transplant recipients [113].
When combined with MMF and prednisone, this SRL regimen was associated with a 27.5%
rate of acute rejection episodes among 40 cadaveric renal transplant recipients. Indeed, the
combination of SRL (Cmin,ss of 10 to 20 μg/L; LC/UV assay) and basiliximab with late
introduction of low dosage CsA has provided excellent prophylaxis of acute rejection episodes
and renal function for primary, non-African-American recipients of cadaveric kidney trans‐
plants that displayed delayed graft function [112,114,115].
In purely Caucasian low-risk liver and kidney-pancreas transplant recipients, Cmin,ss of 6 to
12 μg/L (IMx® assay) in combination with low dosage TRL has been reported to yield low
rates of acute rejection episodes and toxicity [116]. Because of the long half-life and extensive
tissue distribution of the drug, steady-state concentrations are not reached before day 6 after
initiation of therapy or after a dosage change. Thus, daily concentration monitoring is not
necessary; the first SRL measurements should not be obtained before day 4 after inception of,
or change in therapy. Thereafter, recommend monitoring Cmin,ss weekly for the first month
and bi-weekly for the next month, targeting a 5 to 15 μg/L range if CsA is being used concom‐
itantly at Cmin,ss concentrations of 75 to 150 μg/L. If the patient fails to attain these values
despite a dosage of 20mg/day, a full pharmacokinetic study should be performed to assess
whether the defect is due to limited absorption or rapid clearance rates [112]. Modest correla‐
tion (r = 0.59) exists between SRL dose and peak plasma concentration (Cmax) or AUC, but a
good correlation (r = 0.85) exists between trough concentration prior to the dose (minimum
Cmin,ss and AUC. For this reason, Cmin,ss is a simple and useful index for therapeutic
monitoring of SRL [112,117,118].
4.5. Everolimus (EVL)
In April 2010, EVL, a more water-soluble analog of SRL was approved for use in CsA-sparing
regimens, including the requirement for adjusting EVL doses using target trough blood
concentrations in renal transplant patients [51]. EVL, which has greater polarity than SRL, was
developed in an attempt to improve the pharmacokinetic characteristics of SRL, particularly
to increase its oral bioavailability. After a single oral dose of EVL 4mg in 12 healthy volunteers,
it was absorbed rapidly (within 30 minutes after drug intake). The Cmax of EVL amounted to
44.2 ± 13.3 μg/L and was reached (tmax) after 30 minutes (range 0.5–1 hour). The AUC was 219
± 69 μg* h/L. The overall absorption of EVL, like that of SRL, is probably affected by the activity
of P-gp. It is recommended that patients should take the drug consistently with or without
food to reduce fluctuations in drug exposure [119]. In an international study, the pharmaco‐
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kinetics of EVL, were characterized over the first 6 months post-transplant in 731 patients
receiving either 0.75 or 1.5mg bid EVL in addition to CsA and corticosteroids. The within- and
between-patient variability of dose interval AUC was 27% and 31% respectively. There was
no detectable influence of sex, age (16–66 years), or weight (42-132 kg) on AUC, but EVL
exposure was significantly lower by an average of 20 % in blacks. In a study of 659 AUC profiles
the correlation between trough concentration and overall exposure (AUC) there was a
significant linear correlation with a regression coefficient of 0.89 and corresponding coefficient
of determination of 0.79 [120].
For example, see [121] reported that multiple daily dosing of EVL, in doses up to 5 mg/day, is
adequately well tolerated as add-on therapy in stable renal transplant patients receiving
maintenance Neoral® immunosuppression. Similar degrees of correlation between EVL
trough concentration and thrombocytopenia, leukopenia, hypertriglyceridemia, or hypercho‐
lesterolemia in 54 stable renal transplant patients (18-68 years) were found.
4.5.1. Therapeutic drug monitoring
EVL is a drug with a narrow therapeutic index. The limited and variable bioavailability,
intrinsic interindividual pharmacokinetic variability, the number of factors affecting the
pharmacokinetics, and the number of drug interactions limits the use of fixed doses of this
drug. The EVL Cmin is a good surrogate marker of EVL exposure (AUC), and correlates with
pharmacological response and clinical outcomes. Therefore, prospective dose adjustments to
obtain and maintain a therapeutic EVL Cmin have the potential to improve efficacy and reduce
toxicity [122].
A role for EVL drug monitoring has been suggested because of the potential for improving
efficacy and reducing adverse effects, the EVL Cmin is a good surrogate marker of EVL
exposure (AUC), and correlates with pharmacological response and clinical outcomes.
Therefore, prospective dose adjustments to obtain and maintain a therapeutic EVL Cmin have
the potential to improve efficacy and reduce toxicity [123]. Mere clinical monitoring of efficacy
is insufficient because clinical presentations of graft rejection vary for each patient and are
nonspecific. Thus, some authors have used a previously published 9-step decision-making
algorithm to evaluate the utility of TDM for EVL. The recommended therapeutic range for
EVL is a trough concentration of 3 to 8 ng/mL, as concentrations over 3 ng/mL have been
associated with a decreased incidence of rejection, and concentrations >8 ng/mL with increased
toxicity. Patients on EVL who have problems with absorption, who take concurrent cyto‐
chrome P450 inhibitors or inducers, or are noncompliant will attain the greatest benefit from
therapeutic drug monitoring [124].
5. Advances in immunosuppression – Future trends
Maintenance immunosuppressive therapy over the past decade has become more diversified.
Until the mid-1990s, CsA and azathioprine were the cornerstones in maintenance immuno‐
suppressive therapy. Today, these agents have been largely replaced by the newer agents TRL
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and MMF. Triple immunosuppression continues to be the standard, and corticosteroids are
still part of most widely used immunosuppressive protocols. More effective immunosuppres‐
sion has reduced the incidence of acute rejection without a reduction in patient survival [125].
Calcineurin inhibitors are still the cornerstone of current immunosuppressive therapy, but
have important cardiovascular and oncogenic side effects and nephrotoxicity effects that
contributes to the multifactorial process called “chronic allograft dysfunction“, the leading
cause of chronic allograft failure among kidney transplant recipients. New drugs, with a
different mechanism of action, are being developed focusing on a better balance between drug
efficacy and toxicity. These novel compounds interfere with either T-cell mediated or antibody-
mediated rejection [126].
A number of novel drugs are currently under investigation in Phase I, II, or III clinical trials
primarily to replace the nephrotoxic but highly effective calcineurin inhibitors. ISA247
(voclosporine) is a CsA analog with reduced nephrotoxicity in Phase III study. AEB071
(sotrastaurin), a protein kinase C inhibitor, and CP-690550, a JAK3 inhibitor, are small
molecules in Phase II studies EVL is derived from the mTOR inhibitor SRL and is in Phase III
study. Belatacept is a humanized antibody that inhibits T-cell costimulation and has shown
encouraging results in multiple Phase II and III trials. Alefacept and Efaluzimab are humanized
antibodies that inhibit T-cell adhesion and are in Phase I and II clinical trials [127]. Finally, the
exciting field of tissue engineering and stem cell biology with the repopulation of decellular‐
ized organs is ushering in a new paradigm for transplantation. The era of simplified immu‐
nosuppression regimens devoid of toxicities is upon us with the promise of dramatic
improvement in long term survival [128].
6. Conclusions
Monitored drug therapy has undergone a tremendous change over the past quarter of a
century with the increasing availability of advanced techniques like liquid chromatography
with tandem mass spectrometry detection and immunoassays. Currently, the possibility of
accurately and specifically measuring almost any drug in any biological fluid is a reality, and
while TDM has become a standard of care for most immunosuppressive drugs, TDM practices
will continue to evolve with the field of transplantation. New immunosuppressives, such as
sotrastaurin, exhibit pharmacokinetic variability comparable to that seen with currently used
immunosuppressive drugs and may benefit from monitoring therapy [129]. Although TDM
of biologic drugs such as belatacept have not been reported in clinical trials to date, potentially
useful pharmacodynamic assays that can be performed on blood specimens have been
described [51,130]. The information gained through further study in these complex regimens
should provide innovative strategies and new immunosuppressive agents that will serve to
extend the functional life of allografts without toxicity or infection.
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